Maxim Group analyst Anthony Vendetti maintained a Buy rating on Landec Corp (LNDC) yesterday and set a price target of $20. The company’s shares closed yesterday at $11.41, close to its 52-week low of $11.31.
Vendetti observed:
“Market close, LNDC reported slightly lower-than-expected F2Q19 (Nov) revenue and a relatively inline GAAP loss per share. The company significantly reduced its FY19 (May) revenue and EPS guidance for the base business (ex. Yucatan Foods, acquired on 12/1/2018). The conference call is scheduled for tomorrow at 11am ET.”
According to TipRanks.com, Vendetti is a 3-star analyst with an average return of 1.3% and a 47.7% success rate. Vendetti covers the Healthcare sector, focusing on stocks such as Restoration Robotics Inc, Xtant Medical Holdings, and Ra Medical Systems Inc.
Landec Corp has an analyst consensus of Moderate Buy, with a price target consensus of $20.
See today’s analyst top recommended stocks >>
The company has a one-year high of $15.60 and a one-year low of $11.31. Currently, Landec Corp has an average volume of 60.13K.
Based on the recent corporate insider activity of 26 insiders, corporate insider sentiment is positive on the stock. This means that over the past quarter there has been an increase of insiders buying their shares of LNDC in relation to earlier this year. Most recently, in October 2018, Gregory Skinner, the CFO of LNDC bought 8,913 shares for a total of $125,762.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Landec Corp. engages in the design, development, manufacture and sale of health and wellness products for food and biomaterials markets. It operates through the following segments: Packaged Fresh Vegetables, Biomaterials, and Other. The Packaged Fresh Vegetables segment markets and packs specialty packaged whole, and fresh-cut fruit and vegetables.
